Baird analyst David Rescott raised the firm’s price target on TransMedics (TMDX) to $168 from $154 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results which beat expectations and 2026 outlook was above expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $170 from $155 at Evercore ISI
- TransMedics price target raised to $175 from $150 at Oppenheimer
- TransMedics price target raised to $149 from $114 at JPMorgan
- TransMedics price target raised to $160 from $140 at Piper Sandler
- TransMedics price target raised to $152 from $148 at Canaccord